Cardiac safety analysis of trabectedin (T) vs. dacarbazine (D) in patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior anthracycline chemotherapy.
Monday, June 6th /// 8:00 – 11:30 a.m. CDT .
***************************************
Abstrac 11061 :
Patient-reported outcomes from randomized, phase 3 study of trabectedin (T) vs.dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS) .
Monday, June 6th /// 8:00 – 11:30 a.m. CDT .
***************************************
Abstrac 11064 :
Trabectedin (T)-related liver toxicity: Results of a pharmacokinetic study with T in patients with
hepatic dysfunction (OVC1004) and experience from a Phase 3 clinical trial (SAR3007).
Monday, June 6th /// 8:00 – 11:30 a.m. CDT .
****************************************
About YONDELIS® (trabectedin) :
YONDELIS® (trabectedin) is a synthetically produced anti-tumor agent, originally derived from the sea squirt Ecteinascidia turbinata. It works by binding to the DNA of cancer cells and disrupting their normal cell activity, which causes cell death. More information, including the full prescribing information, is available at www.YONDELIS.com.
YONDELIS is approved in nearly 80 countries in North America, Europe, South America and Asia. In October 2015, YONDELIS was FDA approved for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline containing regimen.Under a licensing agreement with PharmaMar, Janssen Products, LP has the rights to develop and sell YONDELIS globally except in Europe, where PharmaMar SA holds the rights, and in Japan, where PharmaMar has granted a license to Taiho Pharmaceutical Co., Ltd.
...